Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Study of inclusive KS0, Lambda, and Lambda -bar production in diffractive gamma p interactions.
Bhadra S, Appel JA, Bartlett DF, Denby BH, Biel J, Bintinger D, Bharadwaj VK, Blodgett DE, Bracker SB, Bronstein J, Daum C, Duncan AL, Eisner AM, Elliott JR, Estabrooks P, Hartner GF, Kalbfleisch GR, Kennett RG, Kumar BR, Losty MJ, Lu A, Luste GJ, Mantsch PM, Martin JF, Morrison RJ, Nash T, Nauenberg U, Pinfold J, Robertson M, Schmidke W, Shahbazian KK, Sheperd RA, Sliwa K, Sokoloff MD, Spalding WJ, Stacey J, Stanfield KC, Streetman M, Summers DJ, Willis SE, Witherell MS, Yellin SJ, Zorn CJ. Bhadra S, et al. Among authors: willis se. Phys Rev Lett. 1985 Dec 16;55(25):2749-2751. doi: 10.1103/PhysRevLett.55.2749. Phys Rev Lett. 1985. PMID: 10032228 No abstract available.
Study of D production in high-energy gamma p interactions.
Sliwa K, Appel JA, Biel J, Bintinger D, Bronstein J, Daum C, Mantsch PM, Nash T, Purohit MV, Schmidke W, Sokoloff MD, Spalding WJ, Stanfield KC, Streetman M, Willis SE, Bharadwaj VK, Denby BH, Eisner AM, Kennett RG, Lu A, Morrison RJ, Summers DJ, Witherell MS, Yellin SJ, Estabrooks P, Pinfold J, Bartlett DF, Bhadra S, Duncan AL, Elliott JR, Nauenberg U, Losty MJ, Kalbfleisch GR, Robertson M, Blodgett DE, Bracker SB, Hartner GF, Kumar BR, Luste GJ, Martin JF, Shahbazian KK, Sheperd RA, Zorn CJ. Sliwa K, et al. Among authors: willis se. Phys Rev D Part Fields. 1985 Sep 1;32(5):1053-1060. doi: 10.1103/physrevd.32.1053. Phys Rev D Part Fields. 1985. PMID: 9956249 No abstract available.
Determining a urinary-specific antibiogram and risk factors of trimethoprim/sulfamethoxazole, ciprofloxacin and multidrug resistance among Enterobacterales in primary care.
Valentine-King M, Hansen MA, Zoorob R, Schlueter M, Matas JL, Willis SE, Danek LCK, Muldrew K, Zare M, Hudson F, Atmar RL, Chou A, Trautner BW, Grigoryan L. Valentine-King M, et al. Among authors: willis se. J Antimicrob Chemother. 2024 Mar 1;79(3):559-563. doi: 10.1093/jac/dkae004. J Antimicrob Chemother. 2024. PMID: 38217846
Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation.
Dillon MT, Guevara J, Mohammed K, Patin EC, Smith SA, Dean E, Jones GN, Willis SE, Petrone M, Silva C, Thway K, Bunce C, Roxanis I, Nenclares P, Wilkins A, McLaughlin M, Jayme-Laiche A, Benafif S, Nintos G, Kwatra V, Grove L, Mansfield D, Proszek P, Martin P, Moore L, Swales KE, Banerji U, Saunders MP, Spicer J, Forster MD, Harrington KJ. Dillon MT, et al. Among authors: willis se. J Clin Invest. 2024 Jan 16;134(2):e175369. doi: 10.1172/JCI175369. J Clin Invest. 2024. PMID: 37934611 Free PMC article. Clinical Trial.
Epitope Lability of Phosphorylated Biomarkers of the DNA Damage Response Pathway Results in Increased Vulnerability to Effects of Delayed or Incomplete Formalin Fixation.
Wiseman EJ, Moss JI, Atkinson J, Baakza H, Hayes E, Willis SE, Waring PM, Rodriguez Canales J, Jones GN. Wiseman EJ, et al. Among authors: willis se. J Histochem Cytochem. 2023 May;71(5):237-257. doi: 10.1369/00221554231174069. Epub 2023 Apr 29. J Histochem Cytochem. 2023. PMID: 37119278 Free PMC article.
Prevalence and predictors of urine culture contamination in primary care: A cross-sectional study.
Hansen MA, Valentine-King M, Zoorob R, Schlueter M, Matas JL, Willis SE, Danek LCK, Muldrew KL, Zare M, Hudson F, Atmar RL, Chou A, Trautner BW, Grigoryan L. Hansen MA, et al. Among authors: willis se. Int J Nurs Stud. 2022 Oct;134:104325. doi: 10.1016/j.ijnurstu.2022.104325. Epub 2022 Jul 11. Int J Nurs Stud. 2022. PMID: 35914376 Free PMC article. Review.
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.
Willis SE, Winkler C, Roudier MP, Baird T, Marco-Casanova P, Jones EV, Rowe P, Rodriguez-Canales J, Angell HK, Ng FSL, Waring PM, Hodgson D, Ledermann JA, Weberpals JI, Dean E, Harrington EA, Barrett JC, Pierce AJ, Leo E, Jones GN. Willis SE, et al. Br J Cancer. 2021 Dec;125(12):1666-1676. doi: 10.1038/s41416-021-01560-1. Epub 2021 Oct 18. Br J Cancer. 2021. PMID: 34663950 Free PMC article.
Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity.
Sacco A, Federico C, Todoerti K, Ziccheddu B, Palermo V, Giacomini A, Ravelli C, Maccarinelli F, Bianchi G, Belotti A, Ribolla R, Favasuli V, Revenko AS, Macleod AR, Willis B, Cai H, Hauser J, Rooney C, Willis SE, Martin PL, Staniszewska A, Ambrose H, Hanson L, Cattaneo C, Tucci A, Rossi G, Ronca R, Neri A, Mitola S, Bolli N, Presta M, Moschetta M, Ross S, Roccaro AM. Sacco A, et al. Among authors: willis se. Blood. 2021 Nov 4;138(18):1705-1720. doi: 10.1182/blood.2020010572. Blood. 2021. PMID: 34077955 Free PMC article.
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib.
Flemington V, Davies EJ, Robinson D, Sandin LC, Delpuech O, Zhang P, Hanson L, Farrington P, Bell S, Falenta K, Gibbons FD, Lindsay N, Smith A, Wilson J, Roberts K, Tonge M, Hopcroft P, Willis SE, Roudier MP, Rooney C, Coker EA, Jaaks P, Garnett MJ, Fawell SE, Jones CD, Ward RA, Simpson I, Cosulich SC, Pease JE, Smith PD. Flemington V, et al. Among authors: willis se. Mol Cancer Ther. 2021 Feb;20(2):238-249. doi: 10.1158/1535-7163.MCT-20-0002. Epub 2020 Dec 3. Mol Cancer Ther. 2021. PMID: 33273059
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.
Fok JHL, Ramos-Montoya A, Vazquez-Chantada M, Wijnhoven PWG, Follia V, James N, Farrington PM, Karmokar A, Willis SE, Cairns J, Nikkilä J, Beattie D, Lamont GM, Finlay MRV, Wilson J, Smith A, O'Connor LO, Ling S, Fawell SE, O'Connor MJ, Hollingsworth SJ, Dean E, Goldberg FW, Davies BR, Cadogan EB. Fok JHL, et al. Among authors: willis se. Nat Commun. 2019 Nov 7;10(1):5065. doi: 10.1038/s41467-019-12836-9. Nat Commun. 2019. PMID: 31699977 Free PMC article.
42 results